New York, Oct. 03, 2022 (GLOBE NEWSWIRE) — Research Nester has published an in-depth market report on “Global cell line development market‘ for the forecast period, i.e. 2022 – 2031, which includes the following factors:
- Market growth over the forecast period
- Detailed regional summary
- market segmentation
- growth accelerator
- challenges
- Key market players and their detailed profiling
Global Cell Line Development Market Size:
The global cell line development market is anticipated to grow at a CAGR of 12.39% during the forecast period 2022-2031. By 2031, the market is expected to reach $14,671 million. The growing demand for monoclonal antibodies is expected to fuel the market growth. Monoclonal antibodies are proteins made in the laboratory. They prove beneficial in fighting various infectious diseases including cancer, Covid-19, migraines and more. Because of their beneficial properties, the FDA has updated approvals for two monoclonal antibody therapies, REGEN-COV (casirivimab and imdevimab) and bamlanivimab and etesevimab (administered together), but limited their use to cases where the patient was likely to have been exposed to it or are infected with a Covid-19 variant susceptible to these therapies.
Request a PDF sample brochure: https://www.researchnester.com/sample-request-713
These monoclonal antibodies have the ability to fight SARS-CoV-2. Also, rising cancer cases are expected to boost demand for monoclonal antibodies, which in turn should boost the market for cell line development. The World Health Organization reports that cancer will be responsible for about 10 million deaths in 2020, or almost one in six, making it the leading cause of death worldwide.
Global Cell Line Development Market: Key Insights
- North America to get the biggest revenue
- Increased government commitment to promote market growth in the Europe region
- CHO cell segment with the largest revenues
Rising Burden of Osteoporosis Drives Market…
